Drug Discovery for Kinetoplastid Diseases: Future Directions.
Journal
ACS infectious diseases
ISSN: 2373-8227
Titre abrégé: ACS Infect Dis
Pays: United States
ID NLM: 101654580
Informations de publication
Date de publication:
08 02 2019
08 02 2019
Historique:
pubmed:
14
12
2018
medline:
18
12
2019
entrez:
14
12
2018
Statut:
ppublish
Résumé
Kinetoplastid parasites have caused human disease for millennia. Significant achievements have been made toward developing new treatments for leishmaniasis (particularly on the Indian subcontinent) and for human African trypanosomiasis (HAT). Moreover, the sustained decrease in the incidence of HAT has made the prospect of elimination a tantalizing reality. Despite the gains, no new chemical or biological entities to treat kinetoplastid diseases have been registered in more than three decades, and more work is needed to discover safe and effective therapies for patients with Chagas disease and leishmaniasis. Advances in tools for drug discovery and novel insights into the biology of the host-parasite interaction may provide opportunities for accelerated progress. Here, we summarize the output from a gathering of scientists and physicians who met to discuss the current status and future directions in drug discovery for kinetoplastid diseases.
Identifiants
pubmed: 30543391
doi: 10.1021/acsinfecdis.8b00298
doi:
Substances chimiques
Antiprotozoal Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
152-157Subventions
Organisme : Medical Research Council
ID : MR/L018853/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/S019650/1
Pays : United Kingdom